Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04892953
Title Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

lung non-small cell carcinoma


Carboplatin + Durvalumab + Paclitaxel

Carboplatin + Durvalumab + Nab-paclitaxel

Carboplatin + Durvalumab + Gemcitabine


Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST